EGFR and non-small cell lung carcinoma: With the development of targeted therapy over the past decade, the emergence of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has brought important breakthroughs to the treatment of advanced NSCLC.